The Scottish Medicines Consortium (SMC) has approved Kite’s CAR T-cell therapy, Yescarta (axi-cel), for treating adult patients with diffuse large B cell lymphoma (DLBCL) and high-grade B-cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback